Lipum will participate at the Naventus Life Science Summit, 29 September at Grand Hôtel in Stockholm. The event is organized by Naventus Corporate Finance together with Setterwalls, Deloitte, FNCA, Nordnet and Nasdaq. In the evening, the same day, Lipum also participate at the event Umeå på Börsen.
For information and registration (the event will be in Swedish): Umeå på börsen
Lipum will also participate at the digital events Annual Biotech in Europe Forum 7-8 October and BIO-Europe Digital 25-28 October.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.